TrialDrug and alcohol dependence2021

Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.

Frances R Levin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.